晚期肺癌患者应用培美曲塞+顺铂化疗联合综合性心理干预的效果分析
|
摘要
目的探究晚期肺癌患者在培美曲塞联合顺铂化疗基础上联合综合性心理干预的效果及对生存质量的影响。方法选取我院收治的160例肺癌晚期患者,随机分为对照组(n=80)和研究组(n=80)。对照组患者在培美曲塞联合顺铂化疗治疗基础上加以常规护理干预,研究组患者在培美曲塞联合顺铂化疗的基础上加以综合性心理干预,观察对比两组患者的治疗有效率、生活质量评分、护理满意度以及焦虑抑郁评分。结果研究组患者的护理满意度显著高于对照组患者(P<0.05);干预前两组患者在社会功能、躯体功能、角色功能以及认知功能等方面无明显差异(P>0.05),干预后研究组患者的生活质量评分显著高于对照组患者(P<0.05);研究组患者治疗有效率明显高于对照组患者(P<0.05);干预前两组患者焦虑抑郁评分无明显差异(P<0.05),干预后研究组患者SAS、SDA评分明显低于对照组患者(P<0.05)。结论在培美曲塞联合顺铂化疗的基础上加以综合性心理干预可显著改善患者的生活质量,并且临床疗效好,护理满意度高,值得临床上进一步推广和使用。
Objective To explore the effect of combined psychological intervention based on pemetrexed and cisplatin chemotherapy in patients with advanced lung cancer and its impact on the quality of life.Methods 160 patients with advanced lung cancer were randomly divided into control group(n=80) and study group(n=80) in our hospital,the patients in the control group were given routine nursing intervention and pemetrexed combined with cisplatin.the patients in the study group were given comprehensive psychological intervention on the basis of pemetrexed combined with cisplatin.The treatment efficiency,quality of life score,nursing satisfaction,and anxiety depression score of patients between the two groups were observed and compared.Results the nursing satisfaction of patients in the study group was significantly higher than that in the control group(P<0.05); the social function,physical function,role function,and cognitive function between the two groups had no significant difference before intervention(P>0.05),life quality score prognosis of patients in study group was significantly higher than that in control group(P<0.05); the effective rate of patients in study group was significantly higher than that in the control group(P<0.05); the anxiety and depression scores of patients between the two group had no significant difference(P<0.05) before the intervention; the SAS and SDA of patients in study group were significantly lower than those in the control group patients(P<0.05).Conclusioncomprehensive psychological intervention based on pemetrexed combined with cisplatin chemotherapy can significantly improve the quality of life of patients,has high clinical efficacy,and patients' satisfaction.It is worthy of further promotion and application in clinical.
Objective To explore the effect of combined psychological intervention based on pemetrexed and cisplatin chemotherapy in patients with advanced lung cancer and its impact on the quality of life.Methods 160 patients with advanced lung cancer were randomly divided into control group(n=80) and study group(n=80) in our hospital,the patients in the control group were given routine nursing intervention and pemetrexed combined with cisplatin.the patients in the study group were given comprehensive psychological intervention on the basis of pemetrexed combined with cisplatin.The treatment efficiency,quality of life score,nursing satisfaction,and anxiety depression score of patients between the two groups were observed and compared.Results the nursing satisfaction of patients in the study group was significantly higher than that in the control group(P<0.05); the social function,physical function,role function,and cognitive function between the two groups had no significant difference before intervention(P>0.05),life quality score prognosis of patients in study group was significantly higher than that in control group(P<0.05); the effective rate of patients in study group was significantly higher than that in the control group(P<0.05); the anxiety and depression scores of patients between the two group had no significant difference(P<0.05) before the intervention; the SAS and SDA of patients in study group were significantly lower than those in the control group patients(P<0.05).Conclusioncomprehensive psychological intervention based on pemetrexed combined with cisplatin chemotherapy can significantly improve the quality of life of patients,has high clinical efficacy,and patients' satisfaction.It is worthy of further promotion and application in clinical.
引文
[1]`Li J,Shangguan DG,Yuan SQ,et al.Research Progression on the Drug Therapy for Elderly Patients with Non-small Cell Lung Cancer[J].Anti-Tumor Pharmacy,2017,7(2):146-151.[李杰,上官丹罡,袁松泉,等.老年非小细胞肺癌患者药物治疗研究进展[J].肿瘤药学,2017,7(2):146-151.]doi:10.3969/j.issn.2095-1264.2017.02.04.
[2]Kimura T,Taniguchi H,Watanabe N,et al.Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wildtype Non-squamous Non-small Cell Lung Cancer:The Central Japan Lung Study Group Trial 0906[J].Anticancer Res,2016,36(4):1767-1771.
[3]Wehler T,Thomas M,Schumann C,et al.A randomized,phase 2 evaluation of the CHK1 inhibitor,LY2603618,administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer[J].Lung Cancer,2017,108:212-216.doi:10.1016/j.lungcan.2017.03.001.
[4]Wu F,Xue WJ,Shi YF,et al.The Effect of Pemetrexed Combined with Cisplatin Therapy for Treatment of Advanced Non-small Cell Lung Cancer Patients[J].Anti-Tumor Pharmacy,2017,7(5):576-580.[吴菲,薛蔚洁,施怡芳,等.培美曲塞联合顺铂治疗晚期非小细胞肺癌的疗效分析[J].肿瘤药学,2017,7(5):576-580.]doi:10.3969/j.issn.2095-1264.2017.05.12.
[5]Tamiya M,Tamiya A,Shiroyama T,et al.Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-na?ve advanced non-squamous nonsmall cell lung cancer with EGFR mutations[J].Invest New Drugs,2017:1-7.doi:10.1007/s10637-017-0527-z.
[6]Kanda S,Goto K,Shiraishi H,et al.Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer:a four arms phase Ib study[J].Ann Oncol,2016,27(12):2242-2250.doi:10.1093/annonc/mdw416.
[7]Chu WL,Yan RN,Cai L,et al.The Effect of Pemetrexed Combined with Cisplatinfor Treatment of Patients with Nonsmall Cell Lung Canceronimmunologic Function[J].AntiTumor Pharmacy,2017,7(5):236-240.[楚文丽,严蕊娜,蔡琳,等.培美曲塞联合顺铂对晚期非小细胞肺癌患者免疫功能的影响及效果评估[J].肿瘤药学,2017,7(5):236-240.]doi:10.3969/j.issn.2095-1264.2017.05.13.
[8]He G,Xiao X,Zou M,et al.Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases:A case report and literature review[J].Medicine(Baltimore),2016,95(32):e4401.doi:10.1097/MD.0000000000004401.
[9]Dumas L,Macklin-Doherty A,Wu X,et al.72 The Royal Marsden NHS Foundation Trust experience of maintenance pemetrexed following first-line cisplatin/pemetrexed in advanced non-squamous lung cancer[J].Lung Cancer,2016,91(1):S26.doi:10.1016/S0169-5002(16)30089-7.
[10]Ma HC,Sui DX,Xu SH.The clinical efficacy of pemetrexed maintenance treatment for advanced lung adenocarcinoma after pemetrexed combined with cisplatin chemotherapy[J].Shandong Med J,2016,56(33):99-101.[马汉宸,隋东昕,徐少华.晚期肺腺癌培美曲塞联合顺铂化疗后应用培美曲塞同药维持治疗的临床疗效[J].山东医药,2016,56(33):99-101.]doi:10.3969/j.issn.1002-266X.2016.33.036.
[11]He Q,Bi X,Ren C et al.Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin Versus Temozolomide for the Treatment of Non-small Cell Lung Cancer with Brain Metastases[J].Anticancer Res,2017,37(8):4711-4716.
[12]Paz-Ares LG,Zimmermann A,Ciuleanu T,et al.Metaanalysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer[J].Lung Cancer,2017,104:45-51.doi:10.1016/j.lungcan.2016.12.007.
[13]Zhou W,Zheng H,Chen N,et al.Three-dimensional speckle tracking in evaluation of the myocardial toxicity of pemetrexed combined with cisplatin chemotherapy in patients with luang cancer[J].lung cancer[J].Acta Univ Med Anhui,2017,52(1):130-134.[周旺,郑慧,陈娜,等.三维斑点追踪技术评价肺癌患者培美曲塞联合顺铂化疗方案的心肌毒性[J].安徽医科大学学报,2017,52(1):130-134.]
[14]He Q,Wang Y,Zou P,et al.Phase II Study of High-Dose Pemetrexed Plus Cisplatin as First-Line Chemotherapy In the Treatment of Patients with Brain Metastases from Lung Adenocarcinoma[J].World Neurosurg,2017,99:758-762.doi:10.1016/j.wneu.2016.03.098.
[2]Kimura T,Taniguchi H,Watanabe N,et al.Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wildtype Non-squamous Non-small Cell Lung Cancer:The Central Japan Lung Study Group Trial 0906[J].Anticancer Res,2016,36(4):1767-1771.
[3]Wehler T,Thomas M,Schumann C,et al.A randomized,phase 2 evaluation of the CHK1 inhibitor,LY2603618,administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer[J].Lung Cancer,2017,108:212-216.doi:10.1016/j.lungcan.2017.03.001.
[4]Wu F,Xue WJ,Shi YF,et al.The Effect of Pemetrexed Combined with Cisplatin Therapy for Treatment of Advanced Non-small Cell Lung Cancer Patients[J].Anti-Tumor Pharmacy,2017,7(5):576-580.[吴菲,薛蔚洁,施怡芳,等.培美曲塞联合顺铂治疗晚期非小细胞肺癌的疗效分析[J].肿瘤药学,2017,7(5):576-580.]doi:10.3969/j.issn.2095-1264.2017.05.12.
[5]Tamiya M,Tamiya A,Shiroyama T,et al.Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-na?ve advanced non-squamous nonsmall cell lung cancer with EGFR mutations[J].Invest New Drugs,2017:1-7.doi:10.1007/s10637-017-0527-z.
[6]Kanda S,Goto K,Shiraishi H,et al.Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer:a four arms phase Ib study[J].Ann Oncol,2016,27(12):2242-2250.doi:10.1093/annonc/mdw416.
[7]Chu WL,Yan RN,Cai L,et al.The Effect of Pemetrexed Combined with Cisplatinfor Treatment of Patients with Nonsmall Cell Lung Canceronimmunologic Function[J].AntiTumor Pharmacy,2017,7(5):236-240.[楚文丽,严蕊娜,蔡琳,等.培美曲塞联合顺铂对晚期非小细胞肺癌患者免疫功能的影响及效果评估[J].肿瘤药学,2017,7(5):236-240.]doi:10.3969/j.issn.2095-1264.2017.05.13.
[8]He G,Xiao X,Zou M,et al.Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases:A case report and literature review[J].Medicine(Baltimore),2016,95(32):e4401.doi:10.1097/MD.0000000000004401.
[9]Dumas L,Macklin-Doherty A,Wu X,et al.72 The Royal Marsden NHS Foundation Trust experience of maintenance pemetrexed following first-line cisplatin/pemetrexed in advanced non-squamous lung cancer[J].Lung Cancer,2016,91(1):S26.doi:10.1016/S0169-5002(16)30089-7.
[10]Ma HC,Sui DX,Xu SH.The clinical efficacy of pemetrexed maintenance treatment for advanced lung adenocarcinoma after pemetrexed combined with cisplatin chemotherapy[J].Shandong Med J,2016,56(33):99-101.[马汉宸,隋东昕,徐少华.晚期肺腺癌培美曲塞联合顺铂化疗后应用培美曲塞同药维持治疗的临床疗效[J].山东医药,2016,56(33):99-101.]doi:10.3969/j.issn.1002-266X.2016.33.036.
[11]He Q,Bi X,Ren C et al.Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin Versus Temozolomide for the Treatment of Non-small Cell Lung Cancer with Brain Metastases[J].Anticancer Res,2017,37(8):4711-4716.
[12]Paz-Ares LG,Zimmermann A,Ciuleanu T,et al.Metaanalysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer[J].Lung Cancer,2017,104:45-51.doi:10.1016/j.lungcan.2016.12.007.
[13]Zhou W,Zheng H,Chen N,et al.Three-dimensional speckle tracking in evaluation of the myocardial toxicity of pemetrexed combined with cisplatin chemotherapy in patients with luang cancer[J].lung cancer[J].Acta Univ Med Anhui,2017,52(1):130-134.[周旺,郑慧,陈娜,等.三维斑点追踪技术评价肺癌患者培美曲塞联合顺铂化疗方案的心肌毒性[J].安徽医科大学学报,2017,52(1):130-134.]
[14]He Q,Wang Y,Zou P,et al.Phase II Study of High-Dose Pemetrexed Plus Cisplatin as First-Line Chemotherapy In the Treatment of Patients with Brain Metastases from Lung Adenocarcinoma[J].World Neurosurg,2017,99:758-762.doi:10.1016/j.wneu.2016.03.098.